<DOC>
	<DOCNO>NCT00772694</DOCNO>
	<brief_summary>Germ cell tumor , relatively rare disease , common malignancy young male , occur frequently testis . The incidence 1 % , increase majority develop country . The testicular cancer extremely important oncological condition due high rate 80-90 % curability , achieve combination chemotherapy surgery . Some 20-30 % patient experience disease progression first line cisplatin-based chemotherapy salvage 2nd line conventional-dose cisplatin-based salvage chemotherapy result long term remission &lt; 50 % patient ( VeIP - vinblastine , ifosfamide , cisplatin , VIP/PEI - ifosfamide , etoposide , cisplatin , TIP - paclitaxel , ifosfamide , cisplatin ) . In multiple relapsed patient 3rd line chemotherapy induce remission 40 % ( gemcitabine , oxaliplatin ) , 23 % RR ( TG - paclitaxel , gemcitabine ) , 20 % CR ( IPO - irinotecan , paclitaxel , oxaliplatin ) , small proportion cure , usually subsequent consolidation surgery . At stage disease usually chemorefractory chemotherapy regimen proven benefit ( 7 ) . The purpose study determine multiple-relapsed chemorefractory pt may benefit sorafenib monotherapy .</brief_summary>
	<brief_title>Sorafenib Monotherapy Inoperable/Recurrent Germ Cell Carcinoma Refractory Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Male patient &gt; 18 year age 2 . Patients histologically proven germ cell neoplasm ( gonadal extragonadal primary ) 3 . Patients must disease amendable cure either surgery chemotherapy 4 . Patients must fail least two cisplatinbased combination chemotherapy regimens . 5 . Failure prior regimen define either : A â‰¥ 25 % increase sum target lesion , new lesion , An increase AFP HCG nadir level . 6 . Patients least one measurable lesion CT scan MRI accord RECIST criterion 7 . Adequate bone marrow , liver renal function , assess longer 14 day treatment start , define follow laboratory test limit : WBC &gt; 2.0 x 109/l platelet &gt; 60 x 109/l , total bilirubin &lt; 2 x upper limit , AST ALT &lt; 5 x upper limit normal , serum creatinine &lt; 2 x UNL 8. WHO Performance Status 0 , 1 , 2 9 . No concurrent chemotherapy radiotherapy 10 . Life expectancy least 12 week 11 . Absence physiological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule 12 . A sign informed consent must obtain prior study specific procedures 13 . All patient must agree use adequate contraception whole study period 1 . Patients fulfil inclusion criterion 2 . Primary radiotherapy field target lesion 3 . Major surgery ( RPLND ) within 4 week start study drug concurrent serious nonhealing wound , ulcer bone fracture . 4 . Known serious active bacterial , viral fungal infection ( &gt; grade II CTCAE ) include HBV , HCV HIV carrier state . 5 . Previous concurrent malignancy except basal cell carcinoma skin 6 . Uncontrolled hypertension . 7 . Thrombotic embolic event last 6 month prior inclusion . 8 . Impairment gastrointestinal tract , GI disease may influence bioavailability oral sorafenib 9 . Substance alcohol abuse ( nicotine use allow ) 10 . Known suspected hypersensitivity sorafenib . 11 . Participants clinical trial use investigational drug within 4 week prior study entry 12 . Prior use investigational licensed angiogenesis RAF kinase MEK inhibitor . 13 . Patient unwilling unable give inform consent 14 . Any condition may investigator 's opinion jeopardize safety patient compliance study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>testicular cancer</keyword>
	<keyword>germ cell cancer</keyword>
	<keyword>sorafenib</keyword>
</DOC>